Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Vaughn

Showing results (21-30 of 94) with videos related to

Pageof 10
Sort By:
Emerging Infectious Diseases|February 8, 2007
The study transplacental chikungunya virus antibody kinetics, ThailandVeerachai Watanaveeradej, Timothy P Endy, Sriluck Simasathien, et al.
Vaccine|February 7, 2013
Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 monthsGeorge Risi, Louise Frenette, Joanne M Langley, et al.
Clinical and Vaccine Immunology : CVI|April 28, 2017
Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled TrialsRobbert G van der Most, Frédéric Clément, Julie Willekens, et al.
The Journal of Infectious Diseases|June 29, 2014
Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of ageTerry Nolan, Patricia Izurieta, Bee-Wah Lee, et al.
Influenza and Other Respiratory Viruses|September 5, 2020
Non-neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant systemDamien Friel, Mary Co, Thierry Ollinger, et al.
Vaccine|April 26, 2015
Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled studyPatricia Izurieta, Woo Joo Kim, Seong-Heon Wie, et al.
The Journal of Infectious Diseases|October 9, 2014
AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trialPope Kosalaraksa, Robert Jeanfreau, Louise Frenette, et al.
The American Journal of Tropical Medicine and Hygiene|January 27, 2004
Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeysKenneth H Eckels, Doria R Dubois, Robert Putnak, et al.
Human Vaccines & Immunotherapeutics|December 9, 2014
Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trialsDavid W Vaughn, Harry Seifert, Anne Hepburn, et al.
The American Journal of Tropical Medicine and Hygiene|November 7, 2007
Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequencesRobert V Gibbons, Siripen Kalanarooj, Richard G Jarman, et al.
Pageof 10

Showing results (21-30 of 94) with videos related to

Sort By:
Pageof 10
Emerging Infectious Diseases|February 8, 2007
The study transplacental chikungunya virus antibody kinetics, ThailandVeerachai Watanaveeradej, Timothy P Endy, Sriluck Simasathien, et al.
Vaccine|February 7, 2013
Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 monthsGeorge Risi, Louise Frenette, Joanne M Langley, et al.
Clinical and Vaccine Immunology : CVI|April 28, 2017
Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled TrialsRobbert G van der Most, Frédéric Clément, Julie Willekens, et al.
The Journal of Infectious Diseases|June 29, 2014
Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of ageTerry Nolan, Patricia Izurieta, Bee-Wah Lee, et al.
Influenza and Other Respiratory Viruses|September 5, 2020
Non-neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant systemDamien Friel, Mary Co, Thierry Ollinger, et al.
Vaccine|April 26, 2015
Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled studyPatricia Izurieta, Woo Joo Kim, Seong-Heon Wie, et al.
The Journal of Infectious Diseases|October 9, 2014
AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trialPope Kosalaraksa, Robert Jeanfreau, Louise Frenette, et al.
The American Journal of Tropical Medicine and Hygiene|January 27, 2004
Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeysKenneth H Eckels, Doria R Dubois, Robert Putnak, et al.
Human Vaccines & Immunotherapeutics|December 9, 2014
Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trialsDavid W Vaughn, Harry Seifert, Anne Hepburn, et al.
The American Journal of Tropical Medicine and Hygiene|November 7, 2007
Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequencesRobert V Gibbons, Siripen Kalanarooj, Richard G Jarman, et al.
Pageof 10